Page last updated: 2024-11-13

bacitracin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bacitracin A: cyclic dodecapeptide antibiotic from Bacillus licheniformis; structure in Merck Index, 9th ed, #942 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

bacitracin A : A homodetic cyclic peptide consisting of (4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carboxylic acid attached head-to-tail to L-leucyl,D-glutamyl, L-lysyl, D-ornityl, L-isoleucyl, D-phenylalanyl, L-histidyl. D-aspartyl and L-asparaginyl residues coupled in sequence and cyclised by condensation of the side-chain amino group of the L-lysyl residue with the C-terminal carboxylic acid group. It is the major component of bacitracin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID56679083
CHEMBL ID1790520
MeSH IDM0086887

Synonyms (4)

Synonym
bacitracin a
ent-bacitracin a (synthetic)
CHEMBL1790520
CLKOFPXJLQSYAH-NXKKORMHSA-N

Research Excerpts

Overview

Bacitracin A is a cyclic dodecapeptide antibiotic produced by Bacillus licheniformis. It forms stoichiometric complexes with divalent cations including Ni2+ and Zn2+.

ExcerptReferenceRelevance
"Bacitracin A (BA) is an excellent polypeptide antibiotic that is active against gram-positive bacteria without triggering multidrug resistance. "( Synthesis, construction, and evaluation of self-assembled nano-bacitracin A as an efficient antibacterial agent in vitro and in vivo.
Gao, X; Hong, W; Liu, M; Niu, S; Qiao, M; Qiu, P; Shi, H; Tian, C; Yang, J; Zhang, D, 2017
)
2.14
"Bacitracin A is a peptide antibiotic which forms stoichiometric complexes with divalent cations, including Ni2+ and Zn2+. "( Studies on the complex formed between bacitracin A and divalent cations.
Baldwin, TO; Gennis, RB; Scogin, DA, 1983
)
1.98
"Bacitracin A is a cyclic dodecapeptide antibiotic produced by Bacillus licheniformis. "( Binding of nickel and zinc ions to bacitracin A.
Gennis, RB; Mosberg, HI; Scogin, DA; Storm, DR, 1980
)
1.98
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID207079In vitro inhibitory concentration required against Staphylococcus aureus (Staphylococcus aureus)2003Bioorganic & medicinal chemistry letters, Jul-07, Volume: 13, Issue:13
Enantiotracin.
AID205877In vitro inhibitory concentration required against Staphylococcus epidermidis (Staphylococcus epidermidis)2003Bioorganic & medicinal chemistry letters, Jul-07, Volume: 13, Issue:13
Enantiotracin.
AID123061In vitro inhibitory concentration required against Micrococcus luteus (Micrococcus luteus)2003Bioorganic & medicinal chemistry letters, Jul-07, Volume: 13, Issue:13
Enantiotracin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (37.25)18.7374
1990's10 (19.61)18.2507
2000's10 (19.61)29.6817
2010's11 (21.57)24.3611
2020's1 (1.96)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.13 (24.57)
Research Supply Index4.03 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other55 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]